Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale

• Status: Not yet recruiting
• Trial end date: 2025-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Migraine attack is an episodic disorder that affects approximately 12% of the population. Previous studies have shown that 41-48% of migraineur have a combination of patent foramen ovale (PFO). Clinical observational studies have been linking medication therapies which include anticoagulation and anti-platelet therapy with the effectiveness in improving migraine symptoms and reducing the frequency of attacks in patients combined with a PFO. However, it has been unclear whether the effectiveness of anticoagulation or anti-platelet therapy outweigh the conventional migraine medication therapy, as a result, we designed a multi-center randomized clinical trial aiming to examine the effectiveness of anticoagulation versus anti-platelet versus migraine medication therapy in migraine patients with PFO and provide a clinical guidance for migraineur.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
• Treatments: Aspirin; Clopidogrel; Metoprolol; Rivaroxaban

Criteria

Inclusion Criteria:

1. Age 18-65 ；

2. Diagnosed migraine by ICHD-3

3. History of migraine longer than 1 year

4. TCD/TTE/TEE diagnosed patent foramen ovale

5. Willing to participant and agree to follow-ups

Exclusion Criteria:

1. Migraine caused by other reason

2. Had TIA/stroke history

3. Hypersensitive or hyposensitive to the study drug

4. With a history of anticoagulation or anti-platelet drug intake 3 month before randomization.

5. With a history of metoprolol intake 3 month before randomization, and migraine attacks did not reduced 50%.